vTv Therapeutics Q2 FY26 net loss widens to $13.1 million; R&D expenses more than doubled to $8.8 million - VTVT News | RalliesvTv Therapeutics Q2 FY26 net loss widens to $13.1 million; R&D expenses more than doubled to $8.8 million
V
VTVT• Trial timeline and cash runway
- Phase 3 CATT1 trial enrollment is expected to finish in Q3 2026; vTv expects cash to fund operations through the topline readout.
- Phase 2a Hybrid CATT1 trial is slated to start before year-end 2026; a cadisegliatin-focused KOL event is planned for Q4 2026.
Q2 loss widens as R&D spending jumps
- vTv Therapeutics posted a Q2 net loss attributable to shareholders of USD 13.1 million, widening from USD 6 million a year earlier.
- R&D expense more than doubled to USD 8.8 million; G&A expense rose 43.1% to USD 5.2 million.
- Cash and cash equivalents totaled USD 86.6 million at June 30, down from USD 88.9 million at Dec. 31.
•
